Hollencrest Capital Management Increases Stake in Zoetis Inc. (NYSE:ZTS)

Hollencrest Capital Management grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 606.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 417 shares of the company’s stock after buying an additional 358 shares during the quarter. Hollencrest Capital Management’s holdings in Zoetis were worth $68,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new position in shares of Zoetis in the 3rd quarter valued at about $31,000. Dunhill Financial LLC raised its position in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the last quarter. Atlantic Edge Private Wealth Management LLC boosted its position in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Quarry LP boosted its holdings in shares of Zoetis by 45.9% during the third quarter. Quarry LP now owns 305 shares of the company’s stock worth $60,000 after purchasing an additional 96 shares during the last quarter. Finally, Asset Planning Inc acquired a new position in Zoetis in the fourth quarter valued at $58,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 over the last three months. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Piper Sandler upped their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. Finally, Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $215.90.

Zoetis Trading Down 1.6 %

NYSE:ZTS opened at $161.74 on Thursday. The business’s 50-day moving average is $166.92 and its two-hundred day moving average is $176.44. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The firm has a market capitalization of $72.43 billion, a PE ratio of 29.57, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.24%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.